Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide

被引:16
|
作者
Croudace, Joanne E. [1 ]
Curbishley, Stuart M. [1 ]
Mura, Manuela [1 ]
Willcox, Carrie R. [1 ]
Illarionov, Petr A. [2 ]
Besra, Gurdyal S. [2 ]
Adams, David H. [1 ]
Lammas, David A. [1 ]
机构
[1] Univ Birmingham, MRC Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England
[2] Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England
基金
英国医学研究理事会;
关键词
D O I
10.1186/1471-2172-9-71
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background : Human CD1d-restricted, invariant natural killer T cells (iNKT) are a unique class of T lymphocytes that recognise glycolipid antigens such as alpha-galactosylceramide (alpha GalCer) and upon T cell receptor (TCR) activation produce both Th1 and Th2 cytokines. iNKT cells expand when cultured in-vitro with alpha GalCer and interleukin 2 (IL-2) in a CD1d-restricted manner. However, the expansion ratio of human iNKT cells varies between individuals and this has implications for attempts to manipulate this pathway therapeutically. We have studied a panel of twenty five healthy human donors to assess the variability in their in-vitro iNKT cell expansion responses to stimulation with CD1d ligands and investigated some of the factors that may influence this phenomenon. Results : Although all donors had comparable numbers of circulating iNKT cells their growth rates in-vitro over 14 days in response to a range of CD1d ligands and IL-2 were highly donor-dependent. Two reproducible donor response patterns of iNKT expansion were seen which we have called 'strong' or 'poor' iNKT responders. Donor response phenotype did not correlate with age, gender, frequency of circulating iNKT, or with the CD1d ligand utilised. Addition of exogenous recombinant human interleukin 4 (IL-4) to 'poor' responder donor cultures significantly increased their iNKT proliferative capacity, but not to levels equivalent to that of 'strong' responder donors. However in 'strong' responder donors, addition of IL-4 to their cultures did not significantly alter the frequency of iNKT cells in the expanded CD3(+) population. Conclusion : (i) in-vitro expansion of human iNKT cells in response to CD1d ligand activation is highly donor variable, (ii) two reproducible patterns of donor iNKT expansion were observed, which could be classified into 'strong' and 'poor' responder phenotypes, (iii) donor iNKT response phenotypes did not correlate with age, gender, frequency of circulating iNKT cells, or with the CD1d ligand utilised, (iv) addition of IL-4 to 'poor' but not 'strong' responder donor cultures significantly increased their in-vitro iNKT cell expansion to aGalCer.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
    Joanne E Croudace
    Stuart M Curbishley
    Manuela Mura
    Carrie R Willcox
    Petr A Illarionov
    Gurdyal S Besra
    David H Adams
    David A Lammas
    BMC Immunology, 9
  • [2] Activation of invariant natural killer T cells by alpha-galactosylceramide ameliorates doxorubicin-induced cardiotoxicity in mice
    Obata, Y.
    Ishimori, N.
    Saito, A.
    Kinugawa, S.
    Nakano, I.
    Kakutani, N.
    Yamanashi, K.
    Anzai, T.
    EUROPEAN HEART JOURNAL, 2019, 40 : 925 - 925
  • [3] ACTIVATION OF NATURAL KILLER T CELLS BY ALPHA-GALACTOSYLCERAMIDE AFFECTS IRON METABOLISM
    Huang, Hua
    Fragoso, Gabriela
    Santos, Manuela
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (05) : E127 - E127
  • [4] Activation of invariant natural killer T cells by alpha-galactosylceramide ameliorates doxorubicin-induced cardiotoxicity in mice
    Obata, Yoshikuni
    Ishimori, Naoki
    Saito, Akimichi
    Kinugawa, Shintaro
    Yokota, Takashi
    Takada, Shingo
    Nakano, Ippei
    Kakutani, Naoya
    Yamanashi, Katsuma
    Anzai, Toshihisa
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (19) : 2358 - 2361
  • [5] Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
    Hsu, Chien-Ya
    Chueh, Yu-Shan
    Kuo, Ming-Ling
    Lee, Pei-Tzu
    Hsiao, Hsiu-Shan
    Huang, Jing-Long
    Lin, Syh-Jae
    PLOS ONE, 2021, 16 (12):
  • [6] Attenuation of invariant Natural Killer T-cell anergy induction through intradermal delivery of α-galactosylceramide
    Bontkes, Hetty J.
    Moreno, Maria
    Hangalapura, Basav
    Lindenberg, Jelle J.
    de Groot, Jan
    Lougheed, Sinead
    van der Vliet, Hans J. J.
    van den Eertwegh, Alfons J. M.
    de Gruijl, Tanja D.
    von Blomberg, B. Mary E.
    Scheper, Rik J.
    CLINICAL IMMUNOLOGY, 2010, 136 (03) : 364 - 374
  • [7] Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide
    Hogan, Andrew E.
    O'Reilly, Vincent
    Dunne, Margaret R.
    Dere, Ravindra T.
    Zeng, Shijuan G.
    O'Brien, Cashel
    Amu, Sylvie
    Fallon, Padraic G.
    Exley, Mark A.
    O'Farrelly, Cliona
    Zhu, Xiangming
    Doherty, Derek G.
    CLINICAL IMMUNOLOGY, 2011, 140 (02) : 196 - 207
  • [8] Localization of lymphocyte apoptosis in murine lymphoid tissues after stimulation of natural killer T cells with alpha-galactosylceramide
    Fujii, H
    Seki, S
    Nakatani, K
    Ikeda, K
    Ikemoto, M
    Nakajima, Y
    Arakawa, T
    Kaneda, K
    ARCHIVES OF HISTOLOGY AND CYTOLOGY, 2003, 66 (05) : 397 - 406
  • [9] Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
    Zhang, Lianjun
    Donda, Alena
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [10] Natural killer T cell ligand alpha-galactosylceramide protects against gut ischemia reperfusion-induced organ injury in mice
    Zhang, Jia
    Bi, Jianbin
    Ren, Yifan
    Du, Zhaoqing
    Li, Teng
    Li, Qingshan
    Ke, Mengyun
    Dong, Jian
    Lv, Yi
    Wu, Rongqian
    CYTOKINE, 2018, 111 : 237 - 245